Biogen : Phase 1b Study On Alzheimer's Disease Meets Primary Objective Of Safety & Tolerability
27/7 04:40
(RTTNews) - A Phase 1b placebo-controlled, multiple ascending dose clinical study data showed that BIIB080/IONIS-MAPTRx met its primary objective of safety and tolerability in patients with mild Alzheimer's disease, Biogen Inc. (BIIB) and Ionis Pharmaceuticals Inc. (IONS) said i...